Skip to main content Accessibility help
  • Print publication year: 2019
  • Online publication date: March 2018

4 - Processing of Pleural and Peritoneal Pathologic Specimens for the Diagnosis of Malignant Mesothelioma

1.WHO (World Health Organization). WHO classification of tumours of the lung, pleura, thymus and heart. 4th ed. Travis, WD, Brambilla, E, Burke, AP, Marx, A, Nicholson, AG, editors. Lyon: IARC Press; 2015.
2.Galateau-Sallé, F, Churg, A, Roggli, V, Travis, WD. The 2015 WHO classification of tumors of the pleura: advances since the 2004 classification. J Thoracic Oncol. 2016;11(2):142–54.
3.Husain, AN, Colby, T, Ordonez, N, Krausz, T, Attanoos, R, Beasley, MB, et al. Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2012 Update of the Consensus Statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2013;137(5):647–67.
4.CAP (College of American Pathologists). Cancer protocols and checklists. 2015. Available from: templates?afrLoop=5315966824823314#
5.RCPA (Royal College of Pathologists of Australasia). Structured pathology reporting of cancer protocols. 2010–2015. Available from:
6.RCP (Royal College of Pathologists). Datasets and tissue pathways. 2015. Available from:
7.Scherpereel, A, Astoul, P, Baas, P, Berghmans, T, Clayson, H, de Vuyst, P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J. 2010;35(3):479–95.
8.Churg, A, Attanoos, R, Borczuck, A, Chirieac, LR, Galateau-Sallé, F, Gibbs, A, et al. Dataset for reporting of malignant mesothelioma of the pleura and peritoneum: recommendations from the International Collaboration on Cancer Reporting (ICCR). Arch Pathol Lab Med. 2016; 140(10):1104–10.
9.Stahel, RA, Weder, W, Felip, E, ESMO Guidelines Working Group. Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19(Suppl 2):ii4344.
10.van Zandwijk, N, Clarke, C, Henderson, D, Musk, AW, Fong, K, Nowak, A, et al. Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. J Thorac Dis. 2013; 5(6):E254307.
11.Henderson, WD, Reid, G, Kao, SC, van Zandwijk, N, Klebe, S. Challenges and controversies in the diagnosis of malignant mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia and biomarkers. J Clin Pathol. 2013; 66(10):847–53.
12.Henderson, WD, Reid, G, Kao, SC, van Zandwijk, N, Klebe, S. Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA. J Clin Pathol. 2013; 66(10):854–61.
13.Goldberg, M, Imbernon, E, Rolland, P, Gilg, Soit Ilg A, Savès, M, de Quillacq, A, et al. The French National Mesothelioma Surveillance Program. Occup Environ Med. 2006;63(6):390–95.
14.Maskell, NA, Butland, RJ; Pleural Diseases Group, Standards of Care Committee, British Thoracic Society. BTS guidelines for the investigation of a unilateral pleural effusion in adults. Thorax. 2003;58(Suppl 2):ii817.
15.Du Rand, I, Maskell, N. Introduction and methods: British Thoracic Society pleural disease guideline 2010. Thorax. 2010;65(Suppl 2):ii1eii3.
16.Roberts, ME, Neville, E, Berrisford, RG, Antunes, G, Ali, NJ, BTS Pleural Disease Guideline Group. Management of a malignant pleural effusion: BritishThoracic Society pleural disease guideline 2010. Thorax. 2010;65(Suppl 2):ii32eii40.
17.Churg, A, Sheffield, BS, Galateau-Sallé, F. New markers for separating benign from malignant mesothelial proliferations: are we there yet? Arch Pathol Lab Med. 2015;140(4):318–21.
18.ATS. Am J Respir Crit Care Med. 2000;162:19872001. Available from:
19.Egan, AM, McPhillips, D, Sarkar, S, Breen, DP. Malignant pleural effusion. Q J Med. 2014;107(3):179–84.
20.Cellerin, L, Marcq, M, Sagan, C, Chailleux, E. Pleurésies malignes révélatrices d'un cancer: comparaison des étiologies avec les pleurésies métastatiques. Rev Mal Respir. 2008;25(9):1104–09.
21.Karoo, RO, Lloyd, TD, Garcea, G, Redway, HD, Robertson, GS. How valuable is ascetic cytology in the detection and management of malignancy. Postgrad Med. 2003;79:292–94.
22.Motherby, H, Nadjari, B, Friegel, P, Kohaus, J, Bocking, A. Diagnostic accuracy of effusion cytology. Diagn Cytopathol. 1999;20(6):350–57.
23.Abrams, LD. A pleural-biopsy punch. Lancet. 1958;1:3031.
24.Von Hoff, DD, LiVolsi, V. Diagnostic reliability of needle biopsy of the parietal pleura. A review of 272 biopsies. Am J Clin Pathol. 1975;64(2):200–03.
25.Cagle, PT, Allen, TC. Pathology of the pleura: what the pulmonologists need to know. Respirology. 2011;16(3):430–38. doi: 10.1111/j.1440–1843.2011.01957.x.
26.Cope, C. New pleural biopsy needle. JAMA 1958;167:1107–08.
27.Tomlinson, JR. Invasive procedures in the diagnosis of pleural disease. Semin Respir Med. 1987;9:3060.
28.Nance, KV, Shermer, RW, Askin, FB. Diagnostic efficacy of pleural biopsy as compared with that of pleural fluid examination. Mod Pathol. 1991;4:320–24.
29.Loddenkemper, R, Boutin, C. Thoracoscopy: present diagnostic and therapeutic indications. Eur Respir J. 1993;6:1544–55.
30.Diacon, AH, Van de Wal, BW, Wyser, C, Smedema, JP, Bezuidenhout, J, Bolliger, CT, et al. Diagnostic tools in tuberculous pleurisy: a direct comparative study. Eur Respir J. 2003;22:589–91.
31.Kirsch, CM, Kroe, DM, Azzi, RL, Jensen, WA, Kagawa, FT, Wehner, JH. The optimal number of pleural biopsy specimens for a diagnosis of tuberculous pleurisy. Chest. 1997;112(3):702–06.
32.Light, RW. Update on tuberculous pleural effusion. Respirology. 2010;15(3):451–58.
33.Maskell, NA, Gleeson, FV, Davies, RJ. Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial. Lancet. 2003;361(9366):1326–30. PubMed PMID: 12711467.
34.Dixon, G, de Fonseka, D, Maskell, N. Pleural controversies: image guided biopsy vs. thoracoscopy for undiagnosed pleural effusions? J Thorac Dis. 2015;7(6):1041–51.
35.Bibby, AC, Maskell, NA. Pleural biopsies in undiagnosed pleural effusions; Abrams vs image-guided vs thoracoscopic biopsies. Curr Opin Pulm Med. 2016;22(4):392–98.
36.Yang, PC, Kuo, SH, Luh, KT. Ultrasonography and ultrasound guided needle biopsy of chest diseases: indications, techniques, diagnostic yields and complications. J Med Ultrasound. 1993;1:5363.
37.Walker, SP, Morley, AJ, Stadon, L, De Fonseka, D, Arnold, DA, Medford, AR, et al. Nonmalignant pleural effusions: a prospective study of 356 consecutive unselected patients. Chest. 2017; 151(5):1099–105. PubMed PMID: 28025056.
38.Attanoos, RL, Gibbs, AR. The comparative accuracy of different pleural biopsy techniques in the diagnosis of malignant mesothelioma. Histopathology. 2008;53(3):340–44. doi: 10.1111/j.1365–2559.2008.03099.x. Epub 2008 Jul 18.)
39.Boutin, C, Astoul, P. Diagnostic thoracoscopy. Clin Chest Med. 1998;19(2):295309.
40.Boutin, C, Schlesser, M, Frenay, C, Astoul, P. Malignant pleural mesothelioa. Eur Respir J. 1998;12:972–81.
41.Greillier, L, Cavailles, A, Fraticelli, A, Scherpereel, A, Barlesi, F, Tassi, G, et al. Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma. Cancer. 2007;110(10):2248–52.
42.Bueno, R, Reblando, J, Glickman, J, Jaklitsch, MT, Lukanich, JM, Sugarbaker, DJ. Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma. Ann Thorac Surg. 2004; 78(5):1774–76.
43.Kao, SC, Yan, TD, Lee, K, Burn, J, Henderson, DW, Klebe, S, et al. Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma. J Thorac Oncol. 2011;6(3):602–05.
44.Rubin, JW, Finney, NR, Borders, BM, Chauvin, EJ. Intrathoracic biopsies, pulmonary wedge excision, and management of pleural disease: is video-assisted closed chest surgery the approach of choice? Am Surg. 1994;60(11):860–63.
45.Litzky, LA, Gal, A. Lung specimen handling and practical considerations. In: Hasleton, P, Fiedler, DB, editors. Spencer Pathology of the Lung, sixth edition, chapter 2. Cambridge: Cambridge University Press; 2013.
46.Opitz, I. Management of malignant pleural mesothelioma – the European experience. J Thorac Dis. 2014;6(Suppl 2):S238–52.
47.D'Amico, TA, Rocco, G. The biomolecular era for thoracic surgeons: the example of the ESTS Biology Club. J Thorac Dis. 2014;6(Suppl 2):S265–71.
48.Nowak, AK, Chansky, K, Rice, DC, Pass, HI, Kindler, HL, Shemanski, L, et al. The IASLC Mesothelioma Staging Project: proposals for revisions of the T descriptors in the forthcoming eighth edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol. 2016;11(12):2089–99.
49.Rice, D, Chansky, K, Nowak, A, Pass, H, Kindler, H, Shemanski, L, et al. The IASLC Mesothelioma Staging Project: proposals for the M descriptors and for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM Classification for Mesothelioma. J Thorac Oncol. 2016;11(12):2100–11.
50.Rusch, VW, Chansky, K, Kindler, HL, Nowak, AK, Pass, HI, Rice, DC, et al. The IASLC Mesothelioma Staging Project: proposals for revisions of the N descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma. J Thorac Oncol. 2016;11(12):2112–19.
51.Pass, H, Giroux, D, Kennedy, C, Ruffini, E, Cangir, AK, Rice, D, et al. The IASLC Mesothelioma Staging Project: improving staging of a rare disease through international participation. J Thorac Oncol. 2016;11(12):2082–88.
52.Pillai, K, Pourgholami, MH, Chua, TC, Morris, DL. Prognostic significance of Ki67 expression in malignant peritoneal mesothelioma. Am J Clin Oncol. 2015;38(4):388–94.
53.Engel, KB, Moore, H. Effects of pre analytical variables on the detection of proteins by immunohistochemistry in formalin fixed paraffin embedded tissue. Archiv Pathol Lab Med. 2011;135:537–43.
54.Khoury, T. Delay to formalin fixation alters morphology and immunohistochemistry for breast carcinoma. Appl Immunohistochem Mol Morphol. 2012;20(6):531–42. PubMed PMID: 22495358.
55.Khoury, T, Sait, S, Hwang, H, Chandrasekhar, R, Wilding, G, Tan, D, et al. Delay to formalin fixation effect on breast biomarkers. Mod Pathol. 2009;22(11):1457–67. PubMed PMID: 19734848.
56.Lightfoote, MM, Ball, DJ, Hannon, WH, Ridderhoh, JC, Vogt, RF. Quality assurance for design control and implementation of immunohistochemistry assays; approved guideline. 2nd edition. Wayne, PA: Clinical and Laboratory Standards Institute (CLSI); 2010.
57.Righi, L, Duregon, E, Vatrano, S, Izzo, S, Giorcelli, J, Rondón-Lagos, M, et al. BRCA1-associated protein 1 (Bap1) immunohistochemical expression as a diagnostic tool in malignant pleural mesothelioma classification: a large retrospective study. J Thorac Oncol. 2016;11(11):2006–17.
58.Hwang, HC, Pyott, S, Rodriguez, S, Cindric, A, Carr, A, Michelsen, C, et al. BAP1 immunohistochemistry and p16 FISH in the diagnosis of sarcomatous and desmoplastic mesotheliomas. Am J Surg Pathol. 2016;40(5):714–18.
59.Sheffield, BS, Hwang, HC, Lee, AF, Thompson, K, Rodriguez, S, Tse, CH, et al. BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations. Am J Surg Pathol. 2015;39(7):977–82.
60.Singhi, AD, Krasinskas, AM, Chourdy, HA, Bartlett, DL, Pingpank, JF, Zeh, HJ, et al. The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma. Mod Pathol. 2016;29(1):1424.
61.Sheffield, BS, Lorette, J, Shen, Y, Marra, MA, Churg, A. Immunohistochemistry for NF2, LATS1/2, and YAP/TAZ fails to separate benign from malignant mesothelial proliferations. Arch Pathol Lab Med. 2016;140(5):391.
62.Grillo, F, Pigozzi, S, Ceriolo, P, Calamaro, P, Fiocca, R, Mastracci, L. Factors affecting immunoreactivity in long-term storage of formalin-fixed paraffin-embedded tissue sections. Histochem Cell Biol. 2015;144(1):9399.
63.Bueno, R, Stawiski, EW, Goldstein, LD, Durinck, S, De Rienzo, A, Modrusan, Z, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48(4):407–16.
64.Hynes, SO, Pang, B, James, JA, Maxwell, P, Salto-Tellez, M. Tissue-based next generation sequencing: application in a universal healthcare system. Br J Cancer. 2017;116(5):553–60. PubMed PMID: 28103613
65.Cree, IA, Deans, Z, Ligtenberg, MJ, Normanno, N, Edsjö, A, Rouleau, E, et al. Guidance for laboratories performing molecular pathology for cancer patients. J Clin Pathol. 2014;67(11):923–31.
66.Deans, ZC, Costa, JL, Cree, I, Dequeker, E, Edsjö, A, Henderson, S, et al. Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL.Virchows Arch. 2017;470(1):520.
67.Aziz, N, Zhao, Q, Bry, L, Driscoll, DK, Funke, B, Gibson, JS, et al. College of American Pathologists’ laboratory standards for next-generation sequencing clinical tests. Arch Pathol Lab Med. 2015;139(4):481–93.